Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fluoroestradiol (18F) is an FDA-approved radiopharmaceutical diagnostic agent used with positron emission tomography (PET) imaging. It is a fluorine-18 radiolabeled analog of 17β-estradiol that binds with high affinity to estrogen receptors (ER). By accumulating in tissues that express functional estrogen receptors, fluoroestradiol (18F) allows for the non-invasive, whole-body visualization and characterization of ER-positive lesions. It is primarily indicated as an adjunct to biopsy in patients with recurrent or metastatic breast cancer to assess ER status and guide endocrine therapy selection.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fluoroestradiol (18F).